For example, studies with DREADD mutant mice suggest that agents able to disrupt hepatocyte Gq, Gs, or Gi signaling may prove useful to restore euglycemia under pathophysiological conditions associated with enhanced hepatic glucose production (e.g. in T2D) (16–18). The gene discussed is GNAI1; the disease is type 2 diabetes mellitus.